PIC
IOVA icon

Portland Investment Counsel’s Iovance Biotherapeutics IOVA Stock Holding History

Portland Investment Counsel’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456K Hold
130,000
– – 0.15% 44
2025
Q4 		$355K Hold
130,000
– – 0.11% 47
2025
Q3 		$282K Hold
130,000
– – 0.08% 47
2025
Q2 		$220K Buy
130,000
+30,000
+30% +$74.6K 0.06% 43
2025
Q1 		$333K Buy
100,000
+45,000
+82% +$232K 0.1% 42
2024
Q4 		$407K Buy
55,000
+15,000
+38% +$139K 0.1% 46
2024
Q3 		$376K Buy
40,000
+10,000
+33% +$94.7K 0.13% 41
2024
Q2 		$241K Buy
30,000
+15,000
+100% +$161K 0.09% 48
2024
Q1 		$212 Hold
15,000
– – 0.06% 46
2023
Q4 		$122K Hold
15,000
– – 0.04% 36
2023
Q3 		$68K Buy
+15,000
New +$97.9K 0.03% 37

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Portland Investment Counsel's IOVA Position: Q1 2026 in Review

Portland Investment Counsel held its Iovance Biotherapeutics (IOVA) position steady in Q1 2026 at 130,000 shares worth $456K. The position accounts for 0.15% of the portfolio, ranked #44.

Portland Investment Counsel first reported a position in IOVA in Q3 2023 and has held it in 11 quarters since. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Portland Investment Counsel held 130,000 shares of Iovance Biotherapeutics worth $456K as of Q1 2026.
  • Portland Investment Counsel left its Iovance Biotherapeutics share count unchanged in Q1 2026.
  • Iovance Biotherapeutics made up 0.15% of Portland Investment Counsel's portfolio in Q1 2026, its #44 holding.
  • Portland Investment Counsel first reported a position in Iovance Biotherapeutics in Q3 2023 and has held it in 11 quarters since.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Portland Investment Counsel's 13F filing for Q1 2026, filed 14 May 2026.